Hoptial La Timone — Clinical Trial Site

16 Registered trials

9 Currently recruiting

Organisation

Hoptial La Timone

Location

Marseille, France

Identifier

ORL-000006264

Address

264 rue Saint Pierre, 13005, France

Departments

Dermatology
Digestive Oncology
Hepato-gastroenterology and oncology
Hepatogastroenterology and Digestive Oncology
medecine interne
Medical Oncology
Neuro-oncologie
oncolgy
Oncologie médicale
Oncology
Service Hématologie Immunologie et oncologie pédiatrique

Clinical trials at this site (16)

Search interface

Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. (NIPISAFE) Pending

2024-518138-10-00 Patients with DMMR and/or MSI metastatic colorectal can 4
PRODIGE 104 – NEOPREDICT A multicenter phase II trial using transcriptomic signatures to personalize neoadjuvant chemotherapy for patients … Pending

2024-519753-11-00 Resectable borderline pancreatic adenocarcinoma 4
PRODIGE 115 (FFCD 2406) ULYSSE : FOLFOX/FOLFIRI + Bévacizumab ou Fruquintinib en 2ème ligne du Cancer Colorectal métastatique (CCRm) : essai… Recruiting

2025-522108-26-00 métastatique colorectal cancer 4 2026-02-19
ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus triflurid… Recruiting

2025-522395-92-00 metastatic oeso-gastric adenocarcinoma 5 2025-12-15
ENGIC 01 - COLOSOTO: A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) … Recruiting

2024-514030-20-00 colorectal cancer 4 2025-08-29
A Phase 1/2a, First-in-human Study to Evaluate BMS-986470 in Healthy Volunteers and Participants with Sickle Cell Disease Recruiting

2023-510283-12-00 Sickle Cell Disease 7 2025-06-12
FIRST LINE CHEMOTHERAPY FOR METASTATIC GASTRO ENTERO PANCREATIC NEUROENDOCRINE CARCINOMA Recruiting

2024-515300-39-00 METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE 4 2024-10-18
SALVOVAR trial: A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVa… Recruiting

2023-508260-30-01 Patients with poor prognostic OVARian cancers based on 5 2024-07-30
Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizu… Recruiting

2024-515788-73-00 MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCE 4 2024-07-30
FFCD 2006 – NEORAF : A MULTI-CENTRE, OPEN-LABEL, PILOT TRIAL EVALUATING THE COMBINATION ENCORAFENIB AND CETUXIMAB IN A NEOADJUVANT SETTING I… Recruiting

2024-514107-34-00 BRAF V600E-MUTATED LOCALISED COLON OR UPPER RECTUM CANC 4 2024-07-18
Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (petosemtamab) as single agent or in combination in advanced solid … Recruiting

2024-513627-16-01 Colorectal cancer metastatic 7 2018-03-28
PEHRICCA : PErioperative CISGEM plus RILVEGOSTOMIG in High-Risk resectable Intrahepatic CholangioCarcinoma Ended

2025-521302-17-00 Hihg risk of cholangiocarcinoma intra hépatic resectabl 10 2026-05-26
An Open-Label, Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) Ended

2023-509201-77-00 Hereditary Angioedema 5 2022-11-02
Loc-R01: Randomized Phase IB/II Study of escalating doses of Lenalidomide and Ibrutinib in association with R-MPV as a targeted induction tr… Ended

2024-515331-30-00 Primary Central Nervous System Lymphoma (PCNSL) 7 2020-10-30
PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patient… Ended

2024-518741-21-00 colon cancer 4 2014-12-23
A 24-week with possible extension, prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel group with a randomiza… Halted

2024-514538-19-00 Mastocytosis 5 2025-11-26